SPARKLE Project – Strengthening Partnerships for Research and Knowledge in Sickle Cell Disease

The SPARKLE Project at the Muhimbili University of Health and Allied Sciences (MUHAS) is an international collaborative initiative focused on strengthening research, clinical care, and innovation in sickle cell disease (SCD). The project aims to build sustainable capacity, enhance knowledge sharing, and accelerate the translation of research findings into better health outcomes for individuals living with SCD in Tanzania and the region.

Project Overview

SPARKLE (Strengthening Partnerships for Research and Knowledge in Lifelong Empowerment) brings together researchers, clinicians, and policymakers from MUHAS and international institutions to address key gaps in sickle cell research, data management, and clinical practice. The project emphasizes partnership, mentorship, and technology-driven solutions that support long-term system strengthening.

Through SPARKLE, MUHAS continues to enhance its leadership role in advancing high-quality research and fostering collaboration across Africa and beyond. The project also promotes local ownership of data and the development of evidence-based health policies.

Objectives

• To strengthen institutional and human capacity for sickle cell research and clinical care.

• To promote data sharing, research collaboration, and innovation in healthcare delivery.

• To enhance mentorship and training for early-career researchers and healthcare professionals.

• To translate research findings into improved clinical and community outcomes.

Impact

The SPARKLE Project has contributed to improved coordination among partners, the development of advanced data systems, and the training of a new generation of scientists dedicated to tackling sickle cell disease. It continues to play a vital role in shaping the future of research and healthcare innovation in Tanzania.

CONSA Project – Consortium on Newborn Screening in Africa

The CONSA Project (Consortium on Newborn Screening in Africa) at the Muhimbili University of Health and Allied Sciences (MUHAS) is part of a multinational initiative aimed at establishing and expanding newborn screening and early intervention programs for sickle cell disease (SCD) across Africa. The project is coordinated globally by the American Society of Hematology (ASH) and implemented in several African countries, including Tanzania.

Project Overview

In Tanzania, MUHAS serves as a national coordinating center for the CONSA Project, leading efforts to integrate newborn screening for sickle cell disease into existing maternal and child health services. The project focuses on early diagnosis, linkage to care, data collection, and policy advocacy to ensure that every child born with sickle cell disease receives timely and effective medical attention.

By building on the strong foundation of the MUHAS Sickle Cell Programme, CONSA promotes a sustainable model for early screening, capacity building, and the creation of regional networks that strengthen healthcare systems for genetic disorders.

Objectives

• To implement and expand newborn screening for sickle cell disease across Tanzania.

• To establish standard protocols for diagnosis, follow-up, and care of affected infants.

• To strengthen laboratory and data management systems for national screening programs.

• To build healthcare capacity through training and mentorship of health professionals.

• To inform national health policies and improve child survival outcomes.

Impact

Through CONSA, MUHAS has contributed to identifying thousands of newborns with sickle cell disease and linking them to specialized care. The project has improved community awareness, strengthened diagnostic infrastructure, and influenced health policies that prioritize early intervention for genetic diseases.

CONSA continues to demonstrate how collaborative science, innovation, and capacity building can transform the future of sickle cell care in Africa.

Errant Therapeutics Project – Advancing Innovative Treatments at MUHAS

The Errant Therapeutics Project at the Muhimbili University of Health and Allied Sciences (MUHAS) is a collaborative research initiative focused on developing and evaluating novel therapies for genetic and hematological diseases, with a particular focus on sickle cell disease. The project represents a major step forward in the pursuit of locally relevant, cutting-edge treatments that improve health outcomes in Tanzania and beyond.

Project Overview

Errant Therapeutics combines scientific innovation with strong clinical research to explore new therapeutic approaches, including gene-based, cellular, and molecular treatments. The project integrates laboratory discovery, preclinical evaluation, and translational studies to bridge the gap between scientific research and patient care.

Working closely with international and regional partners, the MUHAS team is building the foundation for advanced therapeutic capacity in Tanzania — enabling the country to participate in and lead global health innovation for complex diseases like sickle cell anemia.

Objectives

• To develop and test advanced therapeutic strategies for sickle cell and related disorders.

• To strengthen research and laboratory capacity in genomics, molecular biology, and regenerative medicine.

• To foster international collaborations for technology transfer and knowledge exchange.

• To build local expertise for future clinical trials of innovative therapies.

Impact

The Errant Therapeutics Project is positioning MUHAS as a regional leader in advanced biomedical research. It supports Tanzania’s long-term vision of achieving self-reliant, evidence-driven healthcare solutions through science, innovation, and collaboration.

Malaria Project – Advancing Research and Control Efforts in Tanzania

The Malaria Project at the Muhimbili University of Health and Allied Sciences (MUHAS) is dedicated to strengthening research, surveillance, and intervention strategies to combat malaria in Tanzania. The project focuses on understanding malaria transmission dynamics, improving diagnosis and treatment, and developing innovative approaches to reduce the burden of the disease nationwide.

Project Overview

Malaria remains a major public health challenge in Tanzania, affecting millions of people each year, particularly children and pregnant women. The MUHAS Malaria Project brings together multidisciplinary teams of scientists, clinicians, and public health experts to generate evidence that informs national and global malaria control programs.

Through laboratory research, field studies, and partnerships with local health facilities, the project investigates parasite resistance, vector behavior, and the effectiveness of current interventions, while exploring new tools for prevention and treatment.

Objectives

• To strengthen malaria research capacity and innovation at MUHAS.

• To monitor and evaluate malaria control interventions and emerging resistance.

• To promote evidence-based malaria policy and program implementation.

• To train the next generation of researchers and public health practitioners in malaria research.

Impact

The Malaria Project has contributed to improved diagnostic methods, capacity building, and data that guide Tanzania’s National Malaria Control Programme. By combining research, training, and collaboration, MUHAS continues to play a key role in the regional and global effort to eliminate malaria.

K43 Project – Building Research Leadership in Sickle Cell Disease

The K43 Project at the Muhimbili University of Health and Allied Sciences (MUHAS) is a research career development initiative funded through the NIH/Fogarty International Center. The project aims to strengthen research capacity and leadership in sickle cell disease in Tanzania by supporting early- and mid-career scientists to develop independent research skills and establish long-term careers in biomedical research.

Project Overview

The K43 Project focuses on mentorship, advanced training, and collaborative research to enhance local expertise in clinical, translational, and data-driven research on sickle cell disease. Through this program, fellows receive structured mentorship, research support, and access to international collaborations to conduct high-quality studies addressing the health challenges faced by individuals living with sickle cell disease in Tanzania.

Objectives

• To develop a new generation of independent researchers and academic leaders in sickle cell and non-communicable diseases.

• To promote high-impact research that informs policy and improves patient outcomes.

• To strengthen institutional research infrastructure and networks for long-term sustainability.

• To foster collaborations between MUHAS, Tanzanian health institutions, and international research partners.

Impact

The K43 Project has contributed significantly to expanding local research capacity, producing publications in global journals, and mentoring young scientists who are shaping the future of health research in Tanzania. The project exemplifies MUHAS’s commitment to excellence in research, innovation, and capacity building.

Advanced Therapy

At the MUHAS Sickle Cell Programme, we are advancing the frontier of care through innovative therapies that go beyond conventional treatment. Our goal is to bring cutting-edge science closer to patients, transforming the way sickle cell disease is managed and treated.

Focus Areas

1. Gene and Cell-Based Therapies
We are exploring emerging curative approaches such as gene editing, stem cell transplantation, and novel molecular therapies that target the root cause of sickle cell disease.

2. Disease-Modifying Treatments
Our projects evaluate and implement new drug therapies that reduce pain crises, improve quality of life, and minimize long-term complications.

3. Clinical Research and Trials
Through partnerships with national and international collaborators, we conduct clinical trials to assess the safety and effectiveness of advanced therapeutic interventions.

4. Capacity Building and Technology Transfer
We strengthen local capacity for advanced laboratory techniques, cell processing, and genomics to ensure sustainable access to future therapies in Tanzania and the region.

SickleGen – MUHAS, Tanzania

The SickleGen Project at the Muhimbili University of Health and Allied Sciences (MUHAS) is a groundbreaking research initiative focused on understanding the genetic factors that influence the progression and severity of Sickle Cell Disease (SCD) among African populations.

Overview

SickleGen aims to uncover how genetic diversity across African communities affects the manifestation, complications, and treatment response in individuals living with SCD. By studying genetic variations and their clinical impact, the project seeks to identify biomarkers that can guide the development of personalized management and novel treatment strategies.

The MUHAS team collaborates with regional and international partners to integrate genomics, bioinformatics, and clinical data, ensuring that findings directly benefit patient care in Africa.

Goal

To understand how genetics influence the progression of Sickle Cell Disease (SCD) in Africans, and to use this knowledge to inform innovative, evidence-based approaches for management and treatment.

Impact

Through SickleGen, MUHAS continues to strengthen its role as a regional leader in genetic and genomic research, contributing to global efforts to reduce the burden of SCD and improve health outcomes across Africa.

SPARCO Tanzania – MUHAS

The Sickle Pan-African Research Consortium (SPARCO) Tanzania, based at the Muhimbili University of Health and Allied Sciences (MUHAS), is a leading national and regional initiative dedicated to improving research, clinical care, and data systems for sickle cell disease (SCD).

Overview

SPARCO Tanzania is part of a broader African network that includes partner institutions in Ghana, Nigeria, and other countries. The MUHAS team plays a central role in coordinating clinical and research activities, maintaining a robust sickle cell registry, and strengthening national health systems to better address SCD.

Through strong partnerships and local capacity building, SPARCO Tanzania focuses on integrating research with clinical services — ensuring that data-driven insights directly improve patient outcomes. The program also supports training for healthcare workers, researchers, and policymakers to promote sustainable impact in Tanzania and across Africa.

Key Objectives

• To establish and maintain a national SCD registry and database.

• To strengthen healthcare systems and clinical management for SCD patients.

• To promote research collaboration and capacity building in genomics and clinical research.

• To enhance knowledge sharing and policy engagement for better SCD outcomes.

Impact

SPARCO Tanzania has made significant contributions to improving coordination of SCD care, advancing scientific research, and fostering collaboration between national and international partners. Through MUHAS, the initiative continues to empower local researchers and clinicians to lead Africa’s response to sickle cell disease.

SPARCO Clinical Coordinating Center 

The Sickle Pan-African Research Consortium (SPARCO) Clinical Coordinating Center at the Muhimbili University of Health and Allied Sciences (MUHAS) serves as the central hub for clinical coordination, data harmonization, and capacity building in sickle cell disease (SCD) research and care across Africa.

Overview

As part of the broader SPARCO network, which includes partner sites in Nigeria, Ghana, and other African countries, the MUHAS-based Clinical Coordinating Center leads efforts to standardize clinical protocols, strengthen data systems, and enhance patient care models. The center ensures high-quality data collection, ethical clinical practices, and effective collaboration among regional partners.

Through its leadership, MUHAS plays a critical role in advancing SCD research and promoting best practices that improve diagnosis, treatment, and long-term management of patients across sub-Saharan Africa.

Objectives

• To coordinate clinical activities and harmonize protocols across SPARCO sites.

• To strengthen clinical research infrastructure and health data systems.

• To support training and mentorship for healthcare professionals and researchers.

• To enhance quality of care for individuals living with sickle cell disease.

Impact

The SPARCO Clinical Coordinating Center at MUHAS has been instrumental in improving clinical data collection and research capacity in Tanzania and across the SPARCO network. Its work supports the vision of a unified, data-driven approach to sickle cell care and research, empowering African institutions to lead in tackling the burden of genetic blood disorders.